Mitsubishi Tanabe Pharma

Results: 77



#Item
11August 24, 2015 Press Release Mitsubishi Tanabe Pharma Corporation Approval of REMICADE® for I.V. Infusion 100, an Anti-Human TNFα Monoclonal

August 24, 2015 Press Release Mitsubishi Tanabe Pharma Corporation Approval of REMICADE® for I.V. Infusion 100, an Anti-Human TNFα Monoclonal

Add to Reading List

Source URL: www.mt-pharma.co.jp

Language: English - Date: 2015-08-24 01:47:31
    12MedImmune and Tanabe Research Laboratories / Mitsubishi Tanabe Pharma Enter into Strategic Collaboration and Licensing Agreement for the Development of Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugates to Treat

    MedImmune and Tanabe Research Laboratories / Mitsubishi Tanabe Pharma Enter into Strategic Collaboration and Licensing Agreement for the Development of Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugates to Treat

    Add to Reading List

    Source URL: www.mt-pharma.co.jp

    Language: English - Date: 2015-09-23 21:36:35
      13July 27, 2015 Press Release Mitsubishi Tanabe Pharma Corporation Organizational Restructuring

      July 27, 2015 Press Release Mitsubishi Tanabe Pharma Corporation Organizational Restructuring

      Add to Reading List

      Source URL: www.mt-pharma.co.jp

      Language: English - Date: 2015-08-04 04:41:36
        14September 15, 2015 Press Release Mitsubishi Tanabe Pharma Corporation MT-4666 in Alzheimer’s Disease Discontinuation of Global Phase 3 Clinical Trial Program in Japan

        September 15, 2015 Press Release Mitsubishi Tanabe Pharma Corporation MT-4666 in Alzheimer’s Disease Discontinuation of Global Phase 3 Clinical Trial Program in Japan

        Add to Reading List

        Source URL: www.mt-pharma.co.jp

        Language: English - Date: 2015-09-14 18:35:46
          15October 1, 2015 Regeneron Announces Collaboration with Mitsubishi Tanabe Pharma for Investigational Pain Therapy Fasinumab in Asia NGF Antibody Fasinumab Currently in Phase 2/3 Osteoarthritis Trial Tarrytown, N.Y., Oct.

          October 1, 2015 Regeneron Announces Collaboration with Mitsubishi Tanabe Pharma for Investigational Pain Therapy Fasinumab in Asia NGF Antibody Fasinumab Currently in Phase 2/3 Osteoarthritis Trial Tarrytown, N.Y., Oct.

          Add to Reading List

          Source URL: files.shareholder.com

          Language: English
            16September 17, 2015 Press release Company name: Representative: Mitsubishi Tanabe Pharma Corporation

            September 17, 2015 Press release Company name: Representative: Mitsubishi Tanabe Pharma Corporation

            Add to Reading List

            Source URL: www.mt-pharma.co.jp

            Language: English - Date: 2015-09-17 01:34:40
              17Financial Results for the Year Ended March 31, 2015 <Supplement> As of May 8, 2015 Mitsubishi Tanabe Pharma Corporation

              Financial Results for the Year Ended March 31, 2015 As of May 8, 2015 Mitsubishi Tanabe Pharma Corporation

              Add to Reading List

              Source URL: www.mt-pharma.co.jp

              Language: English - Date: 2015-09-11 02:39:50
                18September 9, 2015 Press Release Company name: Mitsubishi Tanabe Pharma Corporation Representative: Masayuki Mitsuka President and Representative Director Code number: 4508, First Section, Tokyo Stock Exchange

                September 9, 2015 Press Release Company name: Mitsubishi Tanabe Pharma Corporation Representative: Masayuki Mitsuka President and Representative Director Code number: 4508, First Section, Tokyo Stock Exchange

                Add to Reading List

                Source URL: www.mt-pharma.co.jp

                Language: English - Date: 2015-09-09 02:34:05
                  19October 2, 2015 Press Release Company name: Mitsubishi Tanabe Pharma Corporation Representative: Masayuki Mitsuka President and Representative Director Code number: 4508, First Section, Tokyo Stock Exchange

                  October 2, 2015 Press Release Company name: Mitsubishi Tanabe Pharma Corporation Representative: Masayuki Mitsuka President and Representative Director Code number: 4508, First Section, Tokyo Stock Exchange

                  Add to Reading List

                  Source URL: www.mt-pharma.co.jp

                  Language: English - Date: 2015-10-01 18:23:57
                    20September 30, 2015 Mitsubishi Tanabe Pharma Corporation Revision to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2016

                    September 30, 2015 Mitsubishi Tanabe Pharma Corporation Revision to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2016

                    Add to Reading List

                    Source URL: www.mt-pharma.co.jp

                    Language: English - Date: 2015-09-30 02:25:43